Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Equity Average (2021 - 2025)

Verrica Pharmaceuticals has reported Equity Average over the past 5 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Equity Average at $3.9 million for Q4 2025, up 117.54% from a year ago — trailing twelve months through Dec 2025 was $3.9 million (up 117.54% YoY), and the annual figure for FY2025 was $7.4 million, up 50.29%.
  • Equity Average for Q4 2025 was $3.9 million at Verrica Pharmaceuticals, up from -$17.3 million in the prior quarter.
  • Over the last five years, Equity Average for VRCA hit a ceiling of $60.1 million in Q2 2023 and a floor of -$23.7 million in Q3 2024.
  • Median Equity Average over the past 5 years was $29.0 million (2022), compared with a mean of $19.4 million.
  • Biggest five-year swings in Equity Average: soared 188.01% in 2023 and later plummeted 233.68% in 2025.
  • Verrica Pharmaceuticals' Equity Average stood at $36.7 million in 2021, then increased by 15.44% to $42.4 million in 2022, then dropped by 26.81% to $31.0 million in 2023, then plummeted by 170.75% to -$22.0 million in 2024, then skyrocketed by 117.54% to $3.9 million in 2025.
  • The last three reported values for Equity Average were $3.9 million (Q4 2025), -$17.3 million (Q3 2025), and -$18.0 million (Q2 2025) per Business Quant data.